Do not administer erythropoiesis stimulating agents (ESA) to patients with chronic kidney disease (CKD) and spontaneous hemoglobin levels between 10 and 11 g/dL with no symptoms of anemization. The same applies to patients who have not been tested for blood ferritin levels and transferrin saturation, at least.

Do not administer erythropoiesis stimulating agents (ESA) to patients with chronic kidney disease (CKD) and spontaneous hemoglobin levels between 10 and 11 g/dL with no symptoms of anemization. The same applies to patients who have not been tested for blood ferritin levels and transferrin saturation, at least.

by | Oct 17, 2018

The target of 10-11 gr/dL of hemoglobin has been identified in patients with chronic kidney disease (CKD) as the hemoglobin level associated with a lower risk of complications, particularly for the cardiovascular system. It is also pointless to administer ESA without...
Do not prescribe antihistamines for preventing asthma in children.

Do not use salmeterol in children with acute asthma.

by | Oct 17, 2018

In children with acute asthma, long-acting beta2-agonists (LABAs) are not recommended, because of slow onset of action (10-20 minutes). Clinical data on safety in children are really limited. Moreover, in children with acute asthma salmeterol monotherapy increases the...
Don’t routinely prescribe benzodiazepines or Z -drugs in elderly patients in case of insomnia as first choice treatment. Physicians should always recommend intermittent use of these drugs.In case of chronic use, evaluate both the indications and the possible occurrence of side effects

Don’t routinely prescribe benzodiazepines or Z -drugs in elderly patients in case of insomnia as first choice treatment. Physicians should always recommend intermittent use of these drugs.In case of chronic use, evaluate both the indications and the possible occurrence of side effects

by | Oct 17, 2018

Several studies show an increased risk of falls and hip fracture in elderly patients taking benzodiazepines or Z-drugs (zolpidem, zopiclone, zaleplon). This risk also exists for safer protocols (i.e. short-term therapies with low-dose and short half-life drugs). The...